The pharmacological properties of antidepressants
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Antidepressant drugs represent one of the main forms of effective treatment for the amelioration of depressive symptoms. Most available antidepressants increase extracellular levels of monoamines. However, it is now recognized that monoamine levels and availability are only part of the story, and that antidepressants whose mechanism of action is mainly based on the modulation of monoaminergic systems may not be able to satisfy the unmet needs of depression. Therefore, a number of compounds, developed for their potential antidepressant activity, are endowed with putative mechanisms of action not affecting traditional monoamine targets. This article briefly reviews, within a mechanistic perspective, the pharmacological profiles of representative antidepressants from each class, including monoamine oxidase inhibitors, tricyclics, norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, norepinephrine and serotonin reuptake inhibitors, antidepressants interacting with dopaminergic, melatonergic, glutamatergic, or neuropeptide systems. The undesirable side effects of currently used antidepressants, which can often be a reason for lack of compliance, are also considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889 · cited 2×
“…adaptations (regulation of intracellular signal transduction pathways and expression of specific target genes) that underlie the therapeutic actions of antidepressants (Wong and Licinio, 2001; Nestler et al., 2002; Tardito et al., 2006; Krishnan and Nestler, 2008; Pittenger and Duman, 2008).”
BackgroundStress, Depression, and Neuroplasticity: A Convergence of Mechanisms
Pittenger, C., & Duman, R. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301574 · Cited by 1,795 · cited 2×
“…adaptations (regulation of intracellular signal transduction pathways and expression of specific target genes) that underlie the therapeutic actions of antidepressants (Wong and Licinio, 2001; Nestler et al., 2002; Tardito et al., 2006; Krishnan and Nestler, 2008; Pittenger and Duman, 2008).”
BackgroundNemeroff, C. B., Widerlöv, E., Bissette, G., Walléus, H., Karlsson, I., Eklund, K., Kilts, C. D., Loosen, P. T., & Vale, W. (1984) · Science · doi:10.1126/science.6334362 · Cited by 1,485 · cited 2×
“…of circadian rhythmicity of cortisol and elevated concentrations of the neuropeptide corticotrophin-releasing factor (CRF) have also been reported (Nemeroff et al., 1984; Deuschle et al., 1997), and hypersecretion of cortisol in depression has been suggested to result in hippocampal volume loss,…”
BackgroundThe role of corticotropin-releasing factor in depression and anxiety disorders
Arborelius, L., Owens, M., Plotsky, P., & Nemeroff, C. (1999) · Journal of Endocrinology · doi:10.1677/joe.0.1600001 · Cited by 1,378 · cited 2×
“Up to 50% of patients with major depression have an associated hypercortisolemia (Mitchell et al., 1996; Arborelius et al., 1999).”
BackgroundMaeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103 · cited 2×
“proposed that enhancement of AMPA to NMDA throughput is a rapid mediator of antidepressant effect (Maeng et al., 2008).”
BackgroundCatecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine
Eisenhofer, G., Kopin, I. J., & Goldstein, D. S. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.3.1 · Cited by 1,072 · cited 6×
“In fact, SSRIs engage a number of postsynaptic (and presynaptic) 5-HT receptors throughout the CNS, and recruit multiple classes of 5-HT receptor (including 5-HT1A, 5-HT1B and 5-HT2A or 5-HT2C).”
BackgroundInfluentialPharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2462 · Cited by 894
Circadian genes, rhythms and the biology of mood disorders
McClung, C. A. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.02.003 · Cited by 666
Research and treatment approaches to depression
Wong, M.-L., & Licinio, J. (2001) · Nature Reviews Neuroscience · doi:10.1038/35072566 · Cited by 656
Lorenzetti, V., Allen, N. B., Fornito, A., & Yücel, M. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.11.021 · Cited by 553
Prevalence of Sexual Dysfunction Among Newer Antidepressants
Clayton, A. H., Pradko, J. F., Croft, H. A., Montano, C. B., Leadbetter, R. A., Bolden-Watson, C., Bass, K. I., Donahue, R. M. J., Jamerson, B. D., & Metz, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0414 · Cited by 542 · cited 2×
“Delayed ejaculation, anorgasmia, and decreased libido can occur in up to 60% of patients (Clayton et al., 2002; Masand and Gupta, 2002), and the effects continue as long as the drug is taken.”
BackgroundAntidepressants and Sleep: A Qualitative Review of the Literature
Wilson, S., & Argyropoulos, S. (2005) · Drugs · doi:10.2165/00003495-200565070-00003 · Cited by 392
Deuschle, M., Schweiger, U., Weber, B., Gotthardt, U., Körner, A., Schmider, J., Standhardt, H., Lammers, C.-H., & Heuser, I. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.1.3689 · Cited by 344
Duloxetine in the Treatment of Major Depressive Disorder: A Double-Blind Clinical Trial
Goldstein, D. J., Mallinckrodt, C., Lu, Y., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0309 · Cited by 334 · cited 1×
“Sexual dysfunction can occur in the course of SNRI treatment, as with SSRIs, but with lower rates (Clayton et al., 2002; Goldstein et al., 2002).”
BackgroundAgomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis
Banasr, M., Soumier, A., Hery, M., Mocaër, E., & Daszuta, A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.11.025 · Cited by 318 · cited 2×
“In contrast, Banasr et al. (2006) reported that chronic treatment with agomelatine increased both cell proliferation and survival of newly formed cells in the ventral dentate gyrus of the hippocampus.”
ResultMasand, P., & Gupta, S. (2002) · Annals of Clinical Psychiatry · doi:10.3109/10401230209147454 · Cited by 311 · cited 6×
“Delayed ejaculation, anorgasmia, and decreased libido can occur in up to 60% of patients (Clayton et al., 2002; Masand and Gupta, 2002), and the effects continue as long as the drug is taken.”
BackgroundInfluentialPlasma Levels of Arginine Vasopressin Elevated in Patients with Major Depression
van Londen, L. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00054-7 · Cited by 306 · cited 1×
“Subsequently, correlations among plasma and CSF concentrations of AVP and depressive symptoms were observed (van Londen et al., 1997; de Winter et al., 2003), whereas antidepressant drugs were found to lower the concentration of AVP (De Bellis et al., 1993).”
BackgroundTardito, D., Perez, J., Tiraboschi, E., Musazzi, L., Racagni, G., & Popoli, M. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.1.7 · Cited by 303 · cited 2×
“…adaptations (regulation of intracellular signal transduction pathways and expression of specific target genes) that underlie the therapeutic actions of antidepressants (Wong and Licinio, 2001; Nestler et al., 2002; Tardito et al., 2006; Krishnan and Nestler, 2008; Pittenger and Duman, 2008).”
BackgroundSelf-citationKeller, M., Montgomery, S., Ball, W., Morrison, M., Snavely, D., Liu, G., Hargreaves, R., Hietala, J., Lines, C., Beebe, K., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.013 · Cited by 286 · cited 2×
“The clinical efficacy of the NK1 receptor antagonist MK869 has not been confirmed (Keller et al., 2006).”
Background(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.4.656 · Cited by 278
Binneman, B., Feltner, D., Kolluri, S., Shi, Y., Qiu, R., & Stiger, T. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07071199 · Cited by 254 · cited 1×
“Unfortunately, clinical findings with antagonists at these sites,for example, CP-316,311, have recently proven disappointing (Binneman et al., 2008).”
BackgroundHow can drug discovery for psychiatric disorders be improved?
Agid, Y., Buzsáki, G., Diamond, D. M., Frackowiak, R., Giedd, J., Girault, J.-A., Grace, A., Lambert, J. J., Manji, H., Mayberg, H., et al. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2217 · Cited by 240
Self-citationCryan, J. F., Bruijnzeel, A. W., Skjei, K. L., & Markou, A. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1445-7 · Cited by 223 · cited 1×
“…and Hyttel, 1999) Bupropion bears a resemblance to NRIs (such as reboxetine) as it elevates both DA and NA (but not 5-HT) levels in frontal cortex (Ascher et al., 1995) but it differs from NRIs (and SSRIs) as it elevates DA levels in the nucleus accumbens (Martin et al., 1990; Cryan et al., 2003).”
BackgroundDiscontinuation Symptoms After Treatment With Serotonin Reuptake Inhibitors: A Literature Review
Zajecka, J., Tracy, K. A., & Mitchell, S. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0702 · Cited by 209 · cited 1×
“The existence of a somatic and psychological ‘SSRI discontinuation syndrome’ upon abrupt drug withdrawal, particularly with SSRIs having a short half-life (e.g. paroxetine or fluvoxamine), is generally self-limiting (Zajecka et al., 1997; Masand and Gupta, 2002; Sadock and Sadock, 2003).”
BackgroundMontgomery, S. A., Kennedy, S. H., Burrows, G. D., Lejoyeux, M., & Hindmarch, I. (2004) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000137184.64610.c8 · Cited by 196
Kole, M. H. P., Swan, L., & Fuchs, E. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02136.x · Cited by 181 · cited 1×
“Tianeptine normalizes the stress-induced changes in the amplitude ratio of NMDA receptor to AMPA/kainate receptor-mediated currents (Kole et al., 2002).”
BackgroundHeilig, M., Zachrisson, O., Thorsell, A., Ehnvall, A., Mottagui-Tabar, S., Sjögren, M., Åsberg, M., Ekman, R., Wahlestedt, C., & Ågren, H. (2004) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(03)00101-8 · Cited by 177 · cited 2×
“A significant reduction in CSF levels of NPY has been demonstrated in depressed patients (Heilig et al., 2004), whereas citalopram was recently found to elevate levels of NPY in the CSF of successfully treated patients (Nikisch et al., 2005).”
BackgroundDopaminergic mechanism of antidepressant action in depressed patients
Willner, P., Hale, A. S., & Argyropoulos, S. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2004.12.010 · Cited by 169 · cited 4×
“frontal cortex can contribute to depressive states (Willner et al., 2005), it has been hypothesized that TCAs may”
BackgroundInfluentialPariante, C. M., Makoff, A., Lovestone, S., Feroli, S., Heyden, A., Miller, A. H., & Kerwin, R. W. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704368 · Cited by 159 · cited 2×
“Desipramine also enhances glucocorticoid receptor function by modulating the membrane steroid transporters (Pariante et al., 2001), and suppresses human cytochrome P450 enzymes and rat protein kinase C (Morishita and Watanabe, 1997; Shin et al., 2002).”
Backgroundvan der Hart, M. G. C., Czéh, B., de Biurrun, G., Michaelis, T., Watanabe, T., Natt, O., Frahm, J., & Fuchs, E. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001130 · Cited by 158 · cited 1×
“Selective antagonists at NK1 sites display antidepressant properties in behavioral models (Holmes et al., 2003), and prevent stress-induced alterations of hippocampal neurogenesis and brain-derived neurotrophic factor expression (van der Hart et al., 2002).”
BackgroundSleep Disorders Medicine: Basic Science, Technical Considerations, and Clinical Aspects
NOFZINGER, E. A. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.1.147-a · Cited by 128
Effects of trazodone on the sleep of depressed subjects—a polygraphic study
Mouret, J., Lemoine, P., Minuit, M. P., Benkelfat, C., & Renardet, M. (1988) · Psychopharmacology · doi:10.1007/bf00172629 · Cited by 116
Bupropion Treatment for Cocaine Abuse and Adult Attention-Deficit/Hyperactivity Disorder
Levin, F. R., Evans, S. M., McDowell, D. M., Brooks, D. J., & Nunes, E. (2002) · Journal of Addictive Diseases · doi:10.1300/j069v21n02_01 · Cited by 102 · cited 2×
“This does not seem to be the case with the selective dopamine reuptake inhibitor and clinically effective antidepressant, bupropion (Rush et al., 1998; Levin et al., 2002), which only displays a weak affinity for DA transporters.”
BackgroundCorticotropin-releasing hormone (CRH) as a regulator of waking
Chang, F.-C., & Opp, M. R. (2001) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(01)00024-0 · Cited by 99 · cited 1×
“Additional potential benefits of antidepressants displaying antagonist properties at CRF1 receptors would be an alleviation of the deleterious impact of depression upon sexual behavior, gastrointestinal function, sleep, and circadian rhythms (Chang and Opp, 2001, 2002; Dirks et al., 2002).”
BackgroundRoiser, J. P., McLean, A., Ogilvie, A. D., Blackwell, A. D., Bamber, D. J., Goodyer, I., Jones, P. B., & Sahakian, B. J. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300659 · Cited by 96 · cited 2×
“…clinically effective antidepressants increase extracellular levels of monoamines, and precursor depletion studies show the importance of functionally intact monoaminergic pathways in the expression and maintenance of their clinical actions (Delgado, 2000; Booij et al., 2003; Roiser et al., 2005).”
BackgroundThe vasopressin V1b receptor as a therapeutic target in stress-related disorders
Griebel, G., Simiand, J., Stemmelin, J., Gal, C., & Steinberg, R. (2003) · Current Drug Target -CNS & Neurological Disorders · doi:10.2174/1568007033482850 · Cited by 74 · cited 2×
“The modulation of several neuropeptide systems has been implicated in the etiology of depression (Griebel et al., 2003).”
BackgroundPapakostas, G. I., Nelson, J. C., Kasper, S., & Möller, H.-J. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.07.005 · Cited by 73 · cited 2×
“of intolerance, appear more frequently when using SSRIs (Papakostas et al., 2008).”
BackgroundKhundakar, A. A., & Thomas, A. J. (2009) · International Psychogeriatrics · doi:10.1017/s104161020999007x · Cited by 50 · cited 2×
“It is now accepted that, apart from altered neurotransmitter levels, morphometric and functional changes in limbic and cortical areas (Khundakar and Thomas, 2009; Lorenzetti et al., 2009a, 2009b; Takahashi et al., 2009a, 2009b), and disturbance in circadian rhythms (McClung, 2007), are prominent…”
BackgroundEffects of Reboxetine on Sleep and Nocturnal Cardiac Autonomic Activity in Patients with Dysthymia
Ferini-Strambi, L., Manconi, M., Castronovo, V., Riva, L., & Bianchi, A. (2004) · Journal of Psychopharmacology · doi:10.1177/026988110401800313 · Cited by 17
Cited by
Novel melatonin-based therapies: potential advances in the treatment of major depression
Hickie, I. B., & Rogers, N. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60095-0 · Cited by 334
Mode of action of agomelatine: Synergy between melatonergic and 5-HT2Creceptors
Racagni, G., Riva, M. A., Molteni, R., Musazzi, L., Calabrese, F., Popoli, M., & Tardito, D. (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.595823 · Cited by 282
Self-citationDo polyphenols enter the brain and does it matter? Some theoretical and practical considerations
Schaffer, S., & Halliwell, B. (2012) · Genes & Nutrition · doi:10.1007/s12263-011-0255-5 · Cited by 178
Fortunato, J. J., Réus, G. Z., Kirsch, T. R., Stringari, R. B., Fries, G. R., Kapczinski, F., Hallak, J. E., Zuardi, A. W., Crippa, J. A., & Quevedo, J. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0451-2 · Cited by 98
Metadata
- Authors
- Racagni, G., & Popoli, M.
- Venue
- International Clinical Psychopharmacology
- Published
- 2010-05
- Volume
- 25
- Issue
- 3
- Pages
- 117-131
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2091652677
- Cited by
- 83
- References
- 41
- FWCI
- 6.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.